Results from other supportive studies using MabThera in combination with other chemotherapy regimens (including CHOP, FCM, PC, PCM) for the treatment of CLL patients have also demonstrated high overall response rates with promising PFS rates without adding relevant toxicity to the treatment.
Rezultati iz drugih podpornih študij z uporabo zdravila MabThera v kombinaciji z drugimi kemoterapijami (vključno s CHOP, FCM, PC, PCM) za zdravljenje bolnikov s KLL so prav tako pokazali visok delež celokupnih odgovorov z obetajočimi preživetji brez napredovanja bolezni brez dodatka pomembne toksičnosti k zdravljenju.